We initiate a Buy rating for 89bio, Inc. (NASDAQ: ETNB ), which, in our view, presents a good long-term opportunity, mainly because of its lead candidate, pegozafermin. This drug might be able to help in two challenging indications withAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ETNB over the next 72 hour ...